| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Introduction
Billion-dollar deals. Hostile takeovers. Reverse mergers. Bidding wars. All of
these are signs that Big Pharma is hungry for deals and is aggressively
seeking, assessing, and consummating alliances on several fronts. No facet of
the biotech, specialty, or generics industries is being ignored; no technology
platform, clinical product, or research program is unexplored or unexamined.
Dealmaking has become the driving force that is bolstering R&D pipelines and
promulgating innovative technology throughout drug discovery and development.
In this report, which focuses on mergers and acquisitions (M&As) in the
18-month period from January 2007 through June 2008, we detail deals, the
strategies that drove them, and the likely future role of M&As.
Get the Answers You Need to Shape Your Strategy
- Multibillion-dollar M&As are not uncommon as Big Pharma and Big Biotech
hunt for biologics, enabling technologies, and products to bolster specifi c
therapy areas. What are the forces driving these acquisitions and the industry
trends that are developing? Which companies are moving to become leaders in
personalized medicine and biosimilars?
- Companies are evolving to become "hybrids" that have a hand in various
market sectors, such as branded pharmaceuticals, generics, and biosimilars.
What is the value of this strategy? Which companies are pursuing it, and how
successful have they been? What, according to our expert commentator, does the
Daiichi Sankyo/Ranbaxy deal reveal about this trend?
- China has been identifi ed as a national market that will become a center
of gravity for the pharmaceutical industry in the near future. How are foreign
investors tapping this potential? What activities are native Chinese
pharmaceutical companies pursuing? How is the traditional Chinese medicines
(TCM) market evolving? What does our expert commentator point out about
opportunities in China?
- M&As are likely to remain a valuable strategy in the pharmaceutical and
biotech dealmaking arsenal. What are fi ve key likely developments that will
sustain the wave of M&As over the next few years?
Scope
- Key markets: technology types, therapeutic areas, drug types (biologics,
biosimilars, generics), geographic markets.
- Tables: ten tables detail M&A activity on a variety of fronts:
billion-dollar deals, technology-driven deals, therapeutic-area-focused deals,
IPO-less acquisitions, company type (big pharma, big biotech, specialty
pharma, generics), and more.
- Expert Commentaries: Greg B. Scott, founder and president, ChinaBio
Accelerator and cofounder and president, Life Science Angels, discusses
early-stage opportunities in China; Peter Wittner, Interpharm Consultancy,
explores the future role of hybrid companies.
TABLE OF CONTENTS
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Billion-Dollar Mergers and Acquisitions
- Technology Access
- Largest Biologics Deals
- Protein Engineering
- Biosimilar Capabilities
- Most Active Therapy Areas
- IPO-Less Private Company Acquisitions
- Extending International Reach to China
- Competitive Advantage Through Size and Scale of Operations
- Modernizing Traditional Chinese Medicines
- Moving Up the Pharmaceutical Value Stream
- Access to Money and Capital Markets
- U.S.-Based IPOs
- Reverse
- Acquisition by a Foreign Company
- Japanese M&A Strategies
- Biologics-Related Acquisitions
- Expanded Global
- Consolidation to Strengthen Domestic Presence
- Bringing Branded and Generic Businesses Together
- Big Pharma
- Building a Leading Position in Personalized Medicine
- Gobbling Up Ever-Earlier Stages of Technology
- Strengthening Therapy Areas
- Acquisitions Related to Technology, Biologics, or Specifi c Diseases
- Big Biotech's Recent M&A Activities
- Substantial Activity in Generics M&As
- Five Expectations That Will Continue to Drive M&As
Experts
- Peter Wittner
- Interpharm Consultancy, London
- Greg B. Scott
- Founder and President, ChinaBio Accelerator and Cofounder and President,
Life Science Angels
Expert Commentaries
- Early-Stage Life Sciences Opportunities in China
- Is the Hybrid Company the Future of the Pharmaceutical Industry?
Tables
- 1. Biologics-Related Mergers and Acquisitions, 2007-2008
- 2. Therapy Areas of Select Mergers and Acquisitions, 2007-2008
- 3. Acquisitions of Private, IPO-Less Companies, 2007-2008
- 4. Mergers and Acquisitions by Chinese Companies, 2007-2008
- 5. Mergers and Acquisitions Based on Traditional Chinese Medicines,
2007-2008
- 6. Mergers and Acquisitions by Chinese Companies That Gain Access to U.S.
Markets, 2007-2008
- 7. Mergers and Acquisitions by Japanese Companies, 2007-2008
- 8. Select Big Pharma and Specialty Pharma Mergers and Acquisitions,
2007-2008
- 9. Big Biotech Mergers and Acquisitions, 2007
- 10. Generic- and Biosimilar-Based Mergers and Acquisitions, 2007-2008
Figures
- 1. Spectrum, Dealmaking and Financing Series
- 2. Billion-Dollar Mergers and Acquisitions, 2007-2008
- 3. Acquisition Values of Private IPO-Less Companies, 2007-2008
- 4. ChinaBioStock Index: Market Capitalization of 17 Chinese Companies
Listed onU.S. Stock Exchanges, May 27, 2008
- 5. Sizes of Big Pharma's Mergers and Acquisitions, 2007-2008
|
